Strata Critical Medical/$SRTA
1D1W1MYTD1Y5YMAX
Capital at risk
About Strata Critical Medical
Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.
- Ticker
- $SRTA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 327
- Headquarters
- New York, United States
- Website
- www.stratacritical.com
SRTA Metrics
BasicAdvanced
$474M
11.36
$0.47
2.26
-
Price and volume
Market cap
$474M
Beta
2.26
52-week high
$6.50
52-week low
$3.95
Average daily volume
1M
Financial strength
Current ratio
2.643
Quick ratio
1.445
Long term debt to equity
0.011
Total debt to equity
0.015
Profitability
EBITDA (TTM)
7.222
Gross margin (TTM)
21.25%
Net profit margin (TTM)
15.71%
Operating margin (TTM)
-3.44%
Revenue per employee (TTM)
$780,000
Management effectiveness
Return on assets (TTM)
-1.86%
Return on equity (TTM)
-9.22%
Valuation
Price to earnings (TTM)
11.365
Price to revenue (TTM)
1.773
Price to book
1.7
Price to tangible book (TTM)
4.22
Price to free cash flow (TTM)
-9.166
Free cash flow yield (TTM)
-10.91%
Free cash flow per share (TTM)
-0.585
Growth
Revenue change (TTM)
66.75%
Earnings per share change (TTM)
-297.29%
3-year revenue growth (CAGR)
10.42%
3-year earnings per share growth (CAGR)
-10.29%
What the Analysts think about SRTA
Analyst ratings (Buy, Hold, Sell) for Strata Critical Medical stock.
Analyst projections of the future price of Strata Critical Medical stock.
Bulls say / Bears say
Q2 2026 revenue surged 60.7 % year-over-year to $72.5 million, driven by organic logistics growth and clinical service acquisitions (Reuters)
Transplant Clinical revenue grew 23.8 % sequentially (15.1 % organically), reflecting accelerating demand for high-margin surgical recovery services (Reuters)
Completed three bolt-on clinical acquisitions in Q2 (Louisville Perfusion Services, Heart and Lung Transplant National Recovery Program, Ohio Valley Perfusion), expanding geographic reach and service scale (SEC)
Q2 2026 net loss of $10.5 million (14.5 % of revenue) underscores ongoing profitability challenges despite strong revenue growth (SEC)
Logistics gross margin compressed to 18.4 %, down from 19.3 % in Q1 due to higher fuel surcharges and an unfavorable trip mix, highlighting margin volatility in core operations (Reuters)
Revenue heavily dependent on transplant volumes, which are subject to fluctuations in organ donation rates, policy changes, and other external factors beyond Strata’s control (SEC)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2026.
SRTA Financial Performance
Revenues and expenses
SRTA Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing SRTA
Fund name | Fund size | $SRTA weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.